Show simple item record

Efficacy and safety analyses of the TALENT trial (GETNE 1509): a phase II study of lenvatinib in patients (pts) with advanced G1/G2 pancreatic (panNETs) and gastrointestinal (ginets) neuroendocrine tumors

dc.contributor.authorCapdevila, J
dc.contributor.authorBongiovanni, A
dc.contributor.authorHernando, J
dc.contributor.authorSpada, F
dc.contributor.authorLopez, C
dc.contributor.authorTeule, A
dc.contributor.authorMerino, X
dc.contributor.authorLamarca, Angela
dc.contributor.authorTafuto, S
dc.contributor.authorCustodio, A
dc.contributor.authorFazio, N
dc.contributor.authorIbrahim, T
dc.date.accessioned2019-04-29T09:49:00Z
dc.date.available2019-04-29T09:49:00Z
dc.date.issued2019en
dc.identifier.citationCapdevila J, Bongiovanni A, Hernando J, Spada F, Lopez C, Teule A, et al. Efficacy and safety analyses of the TALENT trial (GETNE 1509): a phase II study of lenvatinib in patients (pts) with advanced G1/G2 pancreatic (panNETs) and gastrointestinal (ginets) neuroendocrine tumors. Neuroendocrinology. 2019;108:168.en
dc.identifier.urihttp://hdl.handle.net/10541/621792
dc.language.isoenen
dc.titleEfficacy and safety analyses of the TALENT trial (GETNE 1509): a phase II study of lenvatinib in patients (pts) with advanced G1/G2 pancreatic (panNETs) and gastrointestinal (ginets) neuroendocrine tumorsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentVall d'Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO) Barcelona, Spainen
dc.identifier.journalNeuroendocrinologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record